Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting

HIV Medicine

Volumn 7, Issue 3, 2006, Pages 146-155

  Gold, J ^a   Batterham, Marijka ^b   Rekers, H ^c   Harms, M K ^c   Geurts, T B P ^c   Helmyr, P M E ^c   Silva de Mendonca J ^d   Carvalho, L H Falleiros ^e   Panos, G ^f   Pinchera, A ^g   Aiuti, F ^h   Lee, C ⁱ   Horban, A ^j   Gatell, J ^k   Phanuphak, P ^l   Prasithsirikul, W ^m   Gazzard, B ⁿ   Bloch, M ^a   Danner, S A ^o  

^a The Albion Street Centre ^*  (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c NV ORGANON   (Netherlands)

^d State Public Servant Hospital   (Brazil)

^e INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^f 1st IKA Hospital   (Greece)

^g CISANELLO HOSPITAL   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ HOSPITAL KUALA LUMPUR   (Malaysia)

^j SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^k HOSPITAL CLÍNIC   (Spain)

^l KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^m Bamrasnaradura Hospital   (Thailand)

ⁿ CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^o ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

Anabolic steroids; HIV; Nandrolonedecanoate; Testosterone; Weightloss

Indexed keywords

ANTIRETROVIRUS AGENT; NANDROLONE DECANOATE; PLACEBO; TESTOSTERONE PHENYLPROPIONATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; TREATMENT OUTCOME; WASTING SYNDROME; WEIGHT REDUCTION;

ADULT; ANABOLIC AGENTS; ANALYSIS OF VARIANCE; BODY MASS INDEX; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTRIC IMPEDANCE; HIV WASTING SYNDROME; HIV-1; HUMANS; MALE; MIDDLE AGED; NANDROLONE; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33644783705     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00358.x     Document Type: Article

References (34)

1. Batterham M, Garsia R, Greenop P. Prevalence and predictors of HIV associated weight loss in the era of highly active antiretroviral therapy. Int J STD AIDS 2002; 13: 744-747.
2. Dworkin MS, Williamson JM. AIDS wasting syndrome: Trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 2003; 33: 267-273.
3. Silva M, Skolnik PR, Gorbach SL et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998; 12: 1645-1651.
4. Tang AM. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 230-236.
5. Macallan DC, Noble C, Baldwin C et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995; 333: 83-88.
6. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol 1998; 25: 76-81.
7. Grinspoon S, Corcoran C, Lee K et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996; 81: 4051-4058.
8. Ottery F, Walsh D, Strawford A. Pharmacological management of anorexia/ cachexia. Semin Oncol 1998; 25: 35-44.
9. Schambelan M, Mulligan K, Grunfeld C et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125: 873-882.
10. Strawford A, Barbieri T, Neese R et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 137-146.
11. Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis 2003; 36: S69-S78.
12. Moyle GJ, Daar ES, Gertner JM et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35: 367-375.
13. Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Washington, DC: Carnegie Institute of Washington, 1919.
14. Kotler DP, Burastero S, Wang J, Pierson RNJ. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease. Am J Clin Nutr 1996; 64: 489S-497S.
15. Cella DF, VonRoenn J, Lloyd S, Browder HP. The Bristol-Myers Anorexia/ Cachexia Recovery Instrument (BACRI): A brief assessment of patients' subjective response to treatment for anorexia/cachexia. Quality Life Res 1995; 4: 221-231.
16. Cominelli S, Raguso CA, Karsegard L et al. Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: A national study. Nutrition 2002; 18: 583-586.
17. Gold J, High HA, Li Y et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996; 10: 745-752.
18. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl 2001; 24: 232-240.
19. Sattler FR, Jaque SV, Schroeder ET et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1999; 84: 1268-1276.
20. Forbes GB. The effect of anabolic steroids on lean body mass: The dose-response curve. Metabolism 1985; 34: 571-573.
21. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002; 2: 692-699.
22. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 1240-1244.
23. Merenich JA, McDermott MT, Asp AA, Harrison SM, Kidd GS. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. J Clin Endocrinol Metab 1990; 70: 566-571.
24. Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: A prospective study. AIDS 1991; 5: 729-733.
25. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84: 611-616.
26. Bhasin S, Storer TW, Javanbakht M et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. J Am Med Assoc 2000; 283: 763-770.
27. Glazer G. Artherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 1991; 151: 1925-1933.
28. Kopera H. (1993) Side effects and contraindications of anabolic steroids, In: Kopera H. ed. Anabolic-Androgenic Steroids Towards the Year 2000, pp. 262-266. Vienna, Blackwell MZV.
29. Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin Infect Dis 2003; 37 (Suppl. 2): S142-S149.
30. Sattler FR, Schroeder ET, Dube MP et al. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Am J Physiol Endocrinol Metab 2002; 283: E1214-E1222.
31. Gold J, Batterham M Nandrolone decanoate; use in HIV-associated lipodystrophy syndrome: A pilot study. Int J STD AIDS 1999; 10: 558.
32. Von-Roenn JH, Armstrong D, Kotler DP et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121: 393-399.
33. Jager H, Knechten H, Moll A, Weitner L, Fischer H, Schmitt-Rau K. Treatment of HIV-associated wasting with recombinant human growth hormone: Monitoring of body composition changes by bioelectrical impedance analysis (BIA). Eur J Med Res 2002; 7: 103-108.
34. Grinspoon S, Corcoran C, Anderson E et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999; 28: 634-636.